I’ve raised capital globally, deployed capital, and built a breast imaging company from the ground up. I’ve sat on both sides of the table, as the operator making the case and as the investor deciding whether to write the check. In my 25 years in this industry, across emerging markets, women’s health is the one category I keep hearing dismissed as “niche.”
It’s a small word that’s done a lot of damage.
It sounds neutral enough, a shorthand for markets too specialized or too narrow to generate outsized returns. But labels shape behavior. Once a sector gets filed under “niche,” the response is automatic. Funds allocate less capital. Exit expectations shrink before the company has even reached commercialization. It happens deal after deal, on nearly every continent, until it hardens into consensus.
The market disagrees. It has for years. We just haven’t been reading it correctly.
The Market Has Already Told Us the Answer
Markets don’t announce what they believe through conference panels or annual reports. They tell us through capital allocation and acquisition activity. Increasingly, that capital isn’t just moving in the U.S.
The Gates Foundation didn’t commit $2.5 billion through 2030 because women’s health is simply having a moment. Gedeon Richter didn’t just acquire Celmatix’s drug discovery portfolio as a gesture. Those are commercial decisions. They’re made after financial analysis, market modeling, and competitive diligence that has nothing to do with sentiment. Each one is a strategic buyer saying, in the only language that matters, that this is valuable enough to become part of our future, wherever in the world it’s built.
We’ve had years of that signal, and we’ve mostly filed it away as a series of isolated wins instead of what it actually is: a mature, proven investment category hiding behind a word that undersells it.
The narrative just hasn’t caught up.
“Niche” Comes From Outdated Thinking
Part of the problem is historical. For decades, women’s health was shorthand for fertility and pregnancy, unintentionally shrinking the perceived size of the opportunity. Once fertility was addressed, investors often assumed the category was tapped out. I still watch this happen in real time: someone hears “women’s health” and pictures a DTC period tracker, rather than the enterprise platform, diagnostics company, or FDA-cleared device that’s in the deck in front of them.
Women’s health encompasses every stage of life and nearly every medical specialty. Cardiovascular disease remains the leading cause of death among women globally. Autoimmune diseases disproportionately affect women. Osteoporosis, menopause, Alzheimer’s, mental health, metabolic disorders, pelvic floor issues, and maternal health are each multibillion-dollar clinical markets with unmet need in developed and emerging markets. That is healthcare, not a niche.
The Diagnostic Value Doesn’t Stop at Privilege
In early 2025, I went in for a routine mammogram. The radiologist saw something they couldn’t visualize clearly, and my follow-up was scheduled three weeks out.
I run a breast imaging company and helped build the technology used for that mammogram. I knew, intellectually, that I was almost certainly fine. But my nervous system didn’t care what I knew, and those three weeks were hard to shake. The result, when I finally had the follow-up, was exactly what I expected: dense tissue, nothing more.
I had every advantage in that scenario: I have the expertise and the access to a fully built-out diagnostic pathway. Most women, especially those in low-resource settings, don’t. That gap is the commercial opportunity. A cancer-detection technology that shortens the wait, sharpens detection, and cuts unnecessary follow-ups pays off across all of healthcare, in every market. It shows up first in women’s health because that’s where unmet needs have been ignored the longest.
That’s precisely why the opportunity exists.
The Best Investors No Longer Ask About Gender
The most encouraging shift I’ve watched over the past several years has been the entrance of traditional healthcare investors into women’s health. These aren’t funds created specifically to support female founders or advance gender equity. They’re sophisticated healthcare investors looking for strong returns that are increasingly found in companies once dismissed as “femtech.”
That’s the real milestone. Women’s health succeeds when the strongest healthcare funds evaluate women’s health companies exactly as they would evaluate any other opportunity: through the quality of the science, the regulatory pathway, reimbursement potential, the clinical evidence, the team, and the commercial strategy. In other words, when gender becomes less important than execution.
Founders share responsibility here too. While the word “femtech” gave this sector visibility when it needed it, the term can just as easily wall these companies off from mainstream healthcare in an investor’s mind. Some of the strongest businesses I know in this space are regulated medical device companies, diagnostics platforms, pharmaceutical innovators, and clinical infrastructure. They should be underwritten that way, not filed under a category that still reads as optional on an investment committee’s memo.
The Only Thing Still “Niche” Is the Assumption Itself
The exits are already here, and the clinical need is undeniable. The $1-trillion-a-year economic opportunity, per McKinsey Health Institute, is real whether or not the label catches up to it.
I’ve spent my career watching the gap between what the data says and what the room believes. Women’s health is where that gap is widest, everywhere I’ve worked. Any investor acting on that now, while others are still dismissing it as niche, will look back and recognize they got in ahead of everyone else.
The argument is already made. What’s left is recognizing that one of healthcare’s largest markets has been hiding in plain sight all along, and moving on it before the label catches up. The firms that understand that first will spend the next decade investing in and building inside one of healthcare’s most underwritten categories.